Top 50 Biotechnology Startup Investors in United States in October 2023

Portfolio highlights

• AIRNA — AIRNA is on a mission to transform the lives of patients with rare and common diseases by pioneering thediscovery and development of RNA editing therapeutics.
• Generate Biomedicines — Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• Evozyne — We have a new way of thinking about proteins. We've uncovered Nature's hidden rules to build Natural Machines. With our partners, we are changing the world.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• Iambic Therapeutics — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.

Portfolio highlights

• Meeno — Meeno is a relationship mentoring app powered by generative AI
• Rocket.Chat — Explore Rocket.Chat, where we put data privacy into every conversation and enable teams to collaborate seamlessly.
• Pulumi — Pulumi's open source infrastructure as code SDK enables you to create, deploy, and manage infrastructure on any cloud, using your favorite languages.

Portfolio highlights

• Isomark Health — Isomark Health is a patented AI-based, real-time and 100% green breath technology that detects and prevents bacterial and viral infections.
• Rantizo — Rantizo provides drone spraying systems and support services for custom applicators, agribusinesses and contractors. Elevating precision ag.
• Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.

Portfolio highlights

• Spruce Biosciences — Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.
• Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

Portfolio highlights

• K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• Kate Therapeutics — Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.
• Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
• Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.

Portfolio highlights

• Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
• CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.

Portfolio highlights

• Tausight — Tausight is specifically designed to help Healthcare ensure the confidentiality, integrity, and availability of ePHI.
• Candesant Biomedical — Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis. It offers a technology that is based on the principle that alkali metals in contact with water generate energy. The insight was that when the amounts of metal and water are controlled, the result is targeted delivery of energy exactly at the site of the water. Itsdevice is designed to target and inactivate the most active sweat glands.The company was founded in 2016 and is headquartered in San Francisco, California.
• Crossbow Therapeutics — Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets.

Portfolio highlights

• Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
• Actio Biosciences — At Actio, we are leveraging advances in genetics and precision medicine to develop life-changing treatments that target underlying shared biology between rare and common diseases. We are applying expertise in genetics, drug discovery, and data sciences to pinpoint targets that not only cause rare diseases with high unmet need, but that also hold promise in more common indications.
• Diligent Robotics — We build robots like Moxi that assist hospital staff with routine activities so they can focus on caring for patients.

Portfolio highlights

• Senzo — SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST.
• KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
• Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.

Portfolio highlights

• CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
• rabbit — Revolutionizing human-machine interaction
• Vayu Robotics — Vayu Robotics is an AI robotics company that develops and commercializes automotive sensing, autonomous vehicles, and robotics technology.

Portfolio highlights

• Doceree — Doceree is a pharmaceutical advertising & healthcare marketing company which helps in getting a better healthcare services
• Avalyn Pharma — This does NOT display on the home page
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
• Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Portfolio highlights

• Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
• Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
• New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Portfolio highlights

• OOVA — OOVA is a fertility diagnostic company that spun out from Mount Sinai Hospital in New York City. Using patent pending biochemistry and artificial intelligence, OOVA learns a woman’s fertility profile by accurately measuring key hormones over time through daily urine samples. By monitoring this critical balance of hormones, OOVA can help a woman getpregnant, identify reasons she is having trouble getting pregnant, and even expose reproductive health issues like PCOS.
• Raise Green — Raise Green is the climate tech marketplace for local impact investing licensed with the SEC and FINRA to sell private securities.
• Driver Technologies — Turn your phone into a dash cam.

Portfolio highlights

• Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
• CH4 Global — CH4 Global is bending the curve with climate change solutions. We leverage red seaweed to help with methane reduction. Learn more our AgTech Solutions today!
• Mach Industries — Delivering decentralized warfare capabilities to guarantee the defense of freedom.

Portfolio highlights

• Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
• Headway — Headway is a mental healthcare system provider based in New York. It develops a health insurance advisory platform designed to connect patients with therapists and provides administrative support to therapists who don’t typically accept insurance. The company was founded by Andrew Adams, Jake Sussman, Dan Ross, and Kevin Chan in 2019.
• Blackbird — We believe the next great hospitality technology platform should connect restaurants and their customers directly, in meaningful and ongoing ways. Blackbird is founded by a team with a passion for restaurants and a track record of using technology to solve problems.

Portfolio highlights

• Synthekine — Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.
• Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
• Carmot Therapeutics — Drug discovery and development to target the root causes that drive cancer and metabolic diseases using Chemotype Evolution.

Portfolio highlights

• Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
• BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
• Elicit — Elicit is an artificial intelligence research assistant that uses language models to help users automate research workflows. This research assistant finds relevant papers without a perfect keyword match, summarizes takeaways from the papers, and extracts key information from the papers.

Portfolio highlights

• Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
• Aer Therapeutics — Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.
• Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

Portfolio highlights

• Delphi — Delphi is digital cloning that scales time, monetizes knowledge, and interacts audience at scale.
• Ramp — Join thousands of forward-thinking businesses using Ramp to control spend, save time, and automate busywork.
• Pivotal Commware — Pivotal Commware was established in 2016 to commercialize a breakthrough in electromagnetic physics, Holographic Beam Forming™ (HBF). Years ago, Pivotal’s founders recognized that wireless demand for data would outgrow the complex coding, multiplexing and modulation schemes that network operators have deployed thus far. Beamforming was theanswer, but existing high cost, size, weight and power-consuming (C-SWaP) solutions were not. That’s why Pivotal assembled a team experienced in advanced commercial antenna and RF circuit design, advanced DARPA technology programs, and, uniquely, active/nonlinear metamaterials. Beyond technology, Pivotal also offers the depth and breadth of skills to develop integrated, end-to-end solutions.

Portfolio highlights

• Octave — Octave has developed the first of it's kind precision care solution focused on neurodegenerative diseases beginning with Multiple Sclerosis (MS).
• Sound Agriculture — Sound Agriculture is creating a more agile and resilient food system with innovative on-demand crop solutions.
• Slingshot Biosciences — Precise, reliable, and repeatable results. With synthetic cell controls, these goals are achievable in your flow cytometry experiments. Reduce costs, save time and commercialize faster. Beads for spectral compensation, immunophenotyping, viability, and assay controls.

Portfolio highlights

• Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
• Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
• Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

Portfolio highlights

• ImmunoScape — ImmuniScape discovers and develops novel TCR-based therapeutics against solid tumors
• Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
• Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.

Portfolio highlights

• Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
• Alkeus Pharmaceuticals — Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.

Portfolio highlights

• Midi Health — Expert care for women 40+. Made for midlife. Delivered by experienced clinicians. Covered by insurance. Book a visit today.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Portfolio highlights

• Andes — Andes empowers microbes to enable positive action against climate change.
• Dimension Inx — Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois.
• SURGE Therapeutics — SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.

Portfolio highlights

• Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
• Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
• Fractyl Health — Our vision is to develop transformative therapies that have the potential to prevent and eliminate metabolic diseases. We are a mission-driven team of innovators, singularly

Portfolio highlights

• InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
• Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.
• Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

Portfolio highlights

• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
• Crossbow Therapeutics — Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets.

Portfolio highlights

• Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
• MooveAI — MooveAI is an automotive company that provides innovative solutions in end-to-end, predictive road intelligence analytics. Their first approach involves continuously collecting trillions of data points about road networks, including data about connected vehicles, road attributes, such as friction and traffic. The data is then integrated into ourproprietary location analytics platform, where it is verified and analyzed. Finally, actionable insights are provided in the form of road risk scores that describe the relative safety of millions of individual road segments.
• Sharrow Marine — Sharrow Marine is a wholly owned subsidiary of sharrow engineering, a company that develops high-performance propulsion technology for the maritime and aeronautical industries. Their sharrow propeller has applications in all types of commercial marine shipping, aerospace, aviation, industrial and commercial non-propulsion uses, as well as inrecreational marine use.

Portfolio highlights

• Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
• OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
• Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.

Portfolio highlights

• Sequoir — Sequoir is a financial technology firm providing blockchain trading and custody APIs to power banks, credit unions, fintech, and the Web 3.0.
• Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
• Nurse Disrupted — A virtual nursing program that retains nurses & improves hospital finances. Live in 4 weeks. Engaged, happier nurses in days.

Portfolio highlights

• Phase — Microfluidics 3D printing biotech in vitro drug discovery
• Duke University — Duke University is a private research university in Durham, North Carolina. Home of the Blue Devils, Duke University has about 15,000 undergraduate and graduate students and a world-class faculty helping to expand the frontiers of knowledge. The university has a strong commitment to applying knowledge in service to society, both near its NorthCarolina campus and around the world.
• Amalgent Therapeutics — Repurposing Existing Drugs to Make Pain Relief Safer

Portfolio highlights

• Melonfrost — Melonfrost has created a novel way to optimize strains, eliminating the biggest bottleneck in the bioeconomy. By combining machine learning and evolution, our proprietary AI + Hardware platform steers the evolution of cells in real-time. Our algorithms explore the biological space and make decisions, while innovations in robotics, sensing, fluidicsand environmental control replace scientific labor, shaving years off the time to market for bioproducts. Evolution, from millenia to months.
• Hyfé — Hyfé Foods is a biotech company producing ingredients by leveraging fungal fermentation to upcycle water byproducts from food manufacturers.
• Macro Oceans — Macro Oceans develops technology to harness the restorative power of seaweed.

Portfolio highlights

• Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
• COMPASS Pathways — COMPASS is a mental health care company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.
• ADARx Pharmaceuticals — ADARx is a genetic medicine company focusing on the editing of Messenger RNA Targeting transcripts and oligonucleotide-based therapeutics.

Portfolio highlights

• Octave — Octave has developed the first of it's kind precision care solution focused on neurodegenerative diseases beginning with Multiple Sclerosis (MS).
• ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
• Orbital Therapeutics — Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible.

Portfolio highlights

• Colorescience — Know Better Skin with Colorescience. From mineral sunscreen to clinical skincare products, achieve a clear, even complexion and protect your skin from the damaging effects of the sun and environmental aggressors such as pollution. Shop Now!
• Leap Therapeutics — Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
• Proteostasis Therapeutics — Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.

Portfolio highlights

• Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
• Bridge Medicines — MEET BRIDGE MEDICINES Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the
• Sembiosys Genetics — SemBioSys Genetics Inc., a Canadian biotechnology company, announced today that it has signed a feasibility agreement with Dow AgroSciences LLC, of Indianapolis, Indiana, for the Stratosome(TM) Biologics System and its application to animal health biologics. Under the terms of the agreement, SemBioSys and Dow AgroSciences will engage incollaborative research with the aim of determining if the Stratosome(TM) Biologics System can enable the commercialisation of a Dow AgroSciences plant-made vaccine. Under the terms of the agreement, SemBioSys will receive upfront and milestone payments. Further terms of the agreement were not disclosed. "We believe that our Stratosome(TM) Biologics System, with its economic and functional benefits, makes it an outstanding platform for animal health products. We are extremely pleased to be working with Dow AgroSciences in developing their vaccine," said Andrew Baum, president and CEO of SemBioSys."We are very pleased to be working with SemBioSys in evaluating the Stratosome(TM) technology and its application to plant-made biologics for the animal health industry," stated Butch Mercer, Global Business Leader, Animal Health and Nutrition for Dow AgroSciencesThis is the third funded development agreement announced by SemBioSys in the last six months. In December, SemBioSys announced that it had executed a development agreement with Martek Biosciences Corporation (Nasdaq: MATK) to co- develop value-added specialty oil products (DHA containing safflower oil) with potential pharmaceutical and nutraceutical applications. In February, SemBioSys announced that it had entered into an agreement with Syngenta for access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products.About SemBioSys Genetics Inc. (www.sembiosys.com)Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development of therapeutic proteins and oils using its proprietary oilbody-based technology - the Stratosome(TM) Biologics System. Spun out of the University of Calgary in 1994, the company's investors include Bay City Capital, Dow AgroSciences Canada, Inc., Ventures West Management Inc., BDC Venture Capital, University Technologies International Inc., RBC Capital Partners and Maurice Moloney Ph.D. scientific founder and chief scientific officer. In addition to these investors, SemBioSys has received repayable contributions of CAD$5.5MM from Technology Partnerships Canada, an agency of Industry Canada, and CAD$4.9MM from AVAC Ltd. SemBioSys has partnerships with Syngenta Participations AG and Martek Biosciences for the use of its Stratosome(TM) technology for the development of therapeutic products.

Portfolio highlights

• SigNoz — SigNoz is an open-source observability tool to help you find issues in your deployed applications & solve them quickly. It provides logs, metrics, and traces under a single pane of glass. Built with ClickHouse as datastore, it is designed to handle enterprise scale.
• teachme.to — Teachme.to is a community of learners discovering lessons for everything.
• Canid — We believe vaccinating shouldn't be hard and it shouldn't be a distraction from what's most important: taking care of the kids.

Portfolio highlights

• Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
• Avalyn Pharma — This does NOT display on the home page
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Portfolio highlights

• ARTBIO — ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
• Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
• Bicara Therapeutics — Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.

Portfolio highlights

• Layer N — Layer N is a layer 2 network designed to hyper-scale financial applications on Ethereum.
• Roam — Roam is the platform for affordable home ownership. Roam helps homebuyers purchase their next home with a low-interest rate mortgage included.
• Regent — We build all-electric, passenger-carrying, wing-in-ground-effect vehicles to service coastal routes with technology available today.

Portfolio highlights

• Octave — Octave is a national behavioral health practice that’s creating a new standard for care delivery that’s both high-quality and accessible to more people. With in-person and virtual clinics in California and New York, the company offers personalized care plans that can include individual therapy, couples therapy, and groups, while pioneeringrelationships with payers to make care more affordable through insurance. Grounded in science, Octave enables clients to experience profound change that is as measurable as it is meaningful.
• Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
• Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.

Portfolio highlights

• Indigo — Indigo Ag improves farmer profitability, environmental sustainability, and consumer health through the use of natural microbiology and digital technologies in agriculture.
• Harbinger Health — Harbinger Health is a biotechnology company that develops a two-tier testing model for the detection of early cancer with a blood test. The company combines artificial intelligence with insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer bloodtests.
• Generate Biomedicines — Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.

Portfolio highlights

• Harpe Bio — Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. The company was founded in 2020 by Chad Brommer and is headquartered in Raleigh, North Carolina, United States.
• MEND — Mend is the scientifically proven way to heal and enhance your body faster.
• Pluton Biosciences — The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent).